Blood Cancer Journal · 2012 · 118 citations · 63 references
MedicineMolecular GeneticsOncologyCancer GeneticsMolecular OncologyOncogenesCancer CytogeneticsChemotherapy In Hematologic MalignanciesChromosomal TranslocationsHematologic Malignancy TherapyMultiple MyelomaOncogene AmplificationBortezomib TherapyBortezomib-based RegimensFibroblast Growth Factor Receptor 3 (Fgfr3) DisordersMultiple Myeloma TherapyMultiple Myeloma TreatmentMyeloma PathogenesisTherapeutic Resistance MechanismsTranslocations
Multiple myeloma (MM) is a heterogeneous plasma cell disorder characterized by genetic abnormalities, including chromosomal translocations, deletions, duplications and genetic mutations. Translocations involving the immunoglobulin heavy chain region at chromosome 14q32 are observed in approximately 40% of patients with MM. Translocation of oncogenes into this region may lead to their increased expression, contributing to disease initiation, disease progression and therapeutic resistance. The t(4;14) translocation is associated with upregulation of the fibroblast growth factor receptor 3 (FGFR3) and the myeloma SET domain protein. Patients with t(4;14) demonstrate an overall poor prognosis that is only partially mitigated by the use of the novel agents bortezomib and lenalidomide; as such, an unmet medical need remains for patients with this aberration. Preclinical studies of inhibitors of FGFR3 have shown promise in t(4;14) MM, and these studies have led to the initiation of clinical trials. Data from these trials will help to determine the clinical utility of FGFR3 inhibitors for patients with t(4;14) MM and may pave the way for personalized medicine in patients with this incurable disease.
63
International Staging System for Multiple Myeloma
Philip R. Greipp, Jesús F. San Miguel, Brian G.M. Durie et al. · Journal of Clinical Oncology · 2005 · 2.9K citations
Medicine, Hematology, Oncology +14
Improved survival in multiple myeloma and the impact of novel therapies
Shaji Kumar, S. Vincent Rajkumar, Angela Dispenzieri et al. · Blood · 2007 · 2.3K citations · Full text
Medicine, Oncology, Pharmacotherapy +14
Receptor Specificity of the Fibroblast Growth Factor Family
David M. Ornitz, Jennifer S. Colvin, Donald G. McEwen et al. · Journal of Biological Chemistry · 1996 · 1.9K citations · Full text
Receptor Specificity of the Fibroblast Growth Factor Family
Xiuqin Zhang, Omar A. Ibrahimi, Shaun K. Olsen et al. · Journal of Biological Chemistry · 2006 · 1.2K citations · Full text